Biotechnology

Employment trends and layoff analytics for the Biotechnology industry.

46
Total Affected
Since Jan 2024
1
Layoff Events
Across all companies
1
Companies
With layoffs
46
Avg per Event
Employees affected
0
Confirmed
Company verified events
1
Multi-Source
Multiple source verification
0
Severance Data
With severance information

Layoffs Over Time

By Sector

Healthcare
46

Most Common Reasons

Codexis, Inc. implemented a workforce reduction of approximately 24% (46 positions) coinciding with a change in company leadership, with Dr. Alison Moore succeeding Dr. Stephen Dilly as CEO, effective November 7, 2025. This strategic overhaul, announced on November 6, 2025, aims to streamline operations, reduce operational expenses by recognizing an approximate $3.5 million expense in the fourth quarter of 2025, and extend the company's cash runway through 2027. The company is pivoting its strategic focus away from small molecule biocatalysis due to pricing pressures and towards innovative manufacturing solutions in its ECO Synthesis platform for oligonucleotide production. This includes reducing sales and marketing efforts in the small molecule biocatalysis segment. The workforce reduction is expected to be substantially completed by January 2026.
1 event

Most Affected Departments

Small Molecule Biocatalysis (especially sales and marketing)
46
Other departments not aligned with ECO Synthesis platform
46

Most Affected Locations

Redwood City
46
CA
46

Companies in Biotechnology

CODEXIS, INC.
CDXS
46 employees affected · 1 event · Healthcare

Recent Layoff Events

DateCompanyEmployeesReason
Nov 11, 2025
CODEXIS, INC. 5 sources
46 (24.0%)
Codexis, Inc. implemented a workforce reduction of approximately 24% (46 positions) coinciding with a change in company leadership, with Dr. Alison Moore succeeding Dr. Stephen Dilly as CEO, effective November 7, 2025. This strategic overhaul, announced on November 6, 2025, aims to streamline operations, reduce operational expenses by recognizing an approximate $3.5 million expense in the fourth quarter of 2025, and extend the company's cash runway through 2027. The company is pivoting its strategic focus away from small molecule biocatalysis due to pricing pressures and towards innovative manufacturing solutions in its ECO Synthesis platform for oligonucleotide production. This includes reducing sales and marketing efforts in the small molecule biocatalysis segment. The workforce reduction is expected to be substantially completed by January 2026.